The anti-inflammatory drugs edasalonexent and vamorolone [49] have also showed progress in clinical trials for the treatment of DMD by inhibiting the pro-inflammatory regulator NFκβ. The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.